Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 31, 2011. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 550,000 Ordinary shares of 25 pence each.
- Purchase Date: October 31, 2011.
- Price Range: Highest price paid was 1,412.5 pence per share; lowest price paid was 1,380.0 pence per share.
- Treasury Holdings: 509,289,248 shares held in Treasury (9.14% of total issued share capital).
- Total Voting Rights Impact: Including unsettled purchases, Treasury holdings represent 10.10% of current total voting rights.
- Shares in Issue: 5,062,543,373 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 550,000 shares on October 31, 2011. These shares are intended to be held in Treasury. The filing notes that the total number of shares in issue (excluding Treasury) serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (509,289,248) against the company's latest annual report.
- Confirm the total issued share capital to validate the 9.14% Treasury ownership calculation.
- Check the settlement status of the 550,000 shares purchased to reconcile the difference between settled Treasury holdings and the 10.10% voting rights figure.
- Review the shareholder authorization from the May 5, 2011 Annual General Meeting to confirm the scope of the buyback program.